ATX inhibitor 5

Research use only, not for human use.

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.

ATX inhibitor 5 (compound 10g) (IC50s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC).ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β.Cell Proliferation Assay Cell Line:CFs and t-HSC/Cl-6 cells Concentration:0.0001, 0.01, 1, 100, 10000 μM Incubation Time:48 hours Result:Displayed activities against CFs and t-HSC/Cl-6 cells with IC50s of 1.21 and 0.78 μM, respectively.

ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently.Animal Model:Male Konmin mice (8-week old, 22-25 g)Dosage:20, 40 mg/kg Administration:Orally; once daily for two weeks Result:Prominently reduced CCl4-induced hepatic fibrosis level.

——

Angiogenesis

PDE

PDE

——

——

2402772-45-4

474.87

C22H18ClF3N6O

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (526.46 mM; Ultrasonic )

FC(F)(F)c1cccc(Nc2ncnc3CCN(Cc23)C(=O)N\N=C\c2ccc(Cl)cc2)c1

——

(-20℃)

With Ice Pack

≥ 2 years